Changeflow GovPing Healthcare & Life Sciences Qu Biologics Inc. EP3137108A1 Anti-Microbial Im...
Routine Rule Added Final

Qu Biologics Inc. EP3137108A1 Anti-Microbial Immunomodulation

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published EP3137108A1 on April 15, 2026, titled 'ANTI-MICROBIAL IMMUNOMODULATION.' The patent application, filed by Qu Biologics Inc., names inventors Harold David Gunn, Salim Dhanji, and David W. Mullins. The invention is classified under IPC categories A61K 39/108, A61K 39/00, A61P 31/04, and A61P 31/12. Designation extends across all relevant European member states including DE, FR, GB, IT, NL, ES, PL, and 24 others.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.

What changed

The EPO published patent application EP3137108A1 for Qu Biologics Inc. covering anti-microbial immunomodulation technology. The publication includes full applicant and inventor details (Harold David Gunn, Salim Dhanji, David W. Mullins) and International Patent Classification codes A61K 39/108, A61K 39/00, A61P 31/04, and A61P 31/12. The patent is designated across 35 European member and extension states.

For competitors in the immunomodulation or anti-microbial therapeutic space, this publication signals an active patent application by Qu Biologics Inc. in the European market. Parties developing similar technologies should review the published claims upon availability to assess potential freedom-to-operate concerns in EU jurisdictions.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ANTI-MICROBIAL IMMUNOMODULATION

Publication EP3137108A1 Kind: A1 Apr 15, 2026

Applicants

Qu Biologics Inc.

Inventors

GUNN, Harold David, DHANJI, Salim, MULLINS, David W.

IPC Classifications

A61K 39/108 20060101AFI20170824BHEP A61K 39/00 20060101ALI20170824BHEP A61P 31/04 20060101ALI20170824BHEP A61P 31/12 20060101ALI20170824BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3137108A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Clinical investigators
Industry sector
3254.1 Biotechnology
Activity scope
Patent publication Immunomodulation technology Anti-microbial therapy
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!